Infusion sets for subcutaneous drug delivery are described herein. The infusion set integrates a bijel-templated material (BTM) into a cannula such that a portion of the BTM protrudes from the cannula tip into the host tissue. The BTM is a porous, polymeric sponge having a co-continuous architecture with consistent curvature throughout non-constricting, interpenetrating channels, which is critical in mitigation of the deleterious host tissue response, vascularization, and flow redistribution in the implant.

The present invention provides a bio-electrode composition including a polymer compound having both an ionic repeating unit A and a (meth)acrylate repeating unit B, wherein the ionic repeating unit A is a repeating unit selected from the group consisting of sodium salt, potassium salt, and ammonium salt having either or both partial structures shown by the following general formulae (1-1) and (1-2), and the (meth)acrylate repeating unit B is a repeating unit shown by the following general formula (2). ##STR00001##
This can form a living body contact layer for a bio-electrode with excellent electric conductivity, biocompatibility, and light weight, which can be manufactured at low cost and does not cause large lowering of the electric conductivity even when it is wetted with water or dried.

A variety of nitric oxide-releasing vascular grafts and prostheses are provided. Methods of making the nitric oxide-releasing vascular grafts and prostheses are also provided. Methods of administering the nitric oxide-releasing vascular grafts and prostheses to a subject in need thereof are also provided. The nitric oxide-releasing vascular grafts and prostheses have a base layer made of a graft material and a nitric oxide-releasing layer made from a polymer matrix including a plurality of polysiloxanes and a plurality of nitric oxide-donating crosslinking moieties covalently crosslinking polysiloxanes in the plurality of polysiloxanes. In some aspects, the vascular grafts and prostheses can provide for reduced infection rates and increased patency by providing for prolonged local delivery of nitric oxide when implanted in a vessel of a subject in need thereof.

A prosthetic tissue valve and a method of treating the prosthetic tissue valve are provided. The method includes: decreasing a temperature of a chamber carrying the prosthetic tissue valve from a first preset temperature to a second preset temperature in a first cooling rate; decreasing the temperature of the chamber carrying the prosthetic tissue valve from the second preset temperature to a third preset temperature in a second cooling rate; and performing a drying process to the prosthetic tissue valve. The second preset temperature is a critical crystallization temperature and is greater than a crystallization temperature of the prosthetic tissue valve. The third preset temperature is lower than the crystallization temperature of the prosthetic tissue valve, and the second cooling rate is greater than the first cooling rate.

According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a proportion of the particulate coating layer comprising the therapeutic agent and the at least one organic additive melts as a single phase at a lower temperature than the melting point of the therapeutic agent and the at least one organic additive when in pure form; wherein the therapeutic agent is paclitaxel; and wherein the therapeutic agent, when formulated in the coating layer, is stable to sterilization.

The disclosed technology relates to a wound dressing comprising an absorbent layer impregnated or coated with a composition comprising a chelating agent, an amphoteric surfactant, and an anionic surfactant. The invention further relates to methods and uses of the wound dressing.

A tent comprising an exposed surface and an antimicrobial substance applied to the exposed surface. The tent can further include an interior. The exposed surface can be disposed within the interior. The tent can include a fabric. The fabric can provide the exposed surface. The tent can be a medical center. The antimicrobial substance can be a silane quaternary ammonium ion or salt thereof. The silane quaternary ammonium ion can be one or more of: 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium ion, 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride, 3-(trihydroxysilyl)propyldimethyloctadecyl ammonium ion, and 3-(trihydroxysilyl)propyldimethyloctadecyl ammonium chloride.

Antimicrobial formulations and coatings for medical devices and processes therefor are disclosed. The formulations include at least one water permeable polymer with at least one antimicrobial agent in a liquid medium and are prepared by wet milling the components and can form antimicrobial coatings having uniformly dispersed particles having an average size of no greater than 50 microns.

The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

A sensor control device and methods of making them are described. The sensor control device includes an electronics housing and a plug assembly. The electronics housing includes an upper shell matable to a lower mount having a skin-facing surface. The plug assembly is coupled to the electronics housing and includes a sensor module that has a sensor and a sharp module having a sharp. The plug assembly includes a base having a skin-facing surface and a plug portion comprising a lumen therethrough. At least a portion of a surface of the electronics housing or the plug assembly comprises an antimicrobial agent. The antimicrobial agent may be a metal and/or a metal oxide.